Uncertainty factors for chemical risk assessment: Interspecies differences in glucuronidation

Food and Chemical Toxicology

Volumn 39, Issue 12, 2001, Pages 1175-1190

  Walton, K ^a   Dorne, J L ^a   Renwick, A G ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Glucuronidation; Interspecies; Metabolism; Toxicokinetics; Uncertainty factors

Indexed keywords

CARPROFEN; CLOFIBRIC ACID; LAMOTRIGINE; LORAZEPAM; MORPHINE; OXAZEPAM; PARACETAMOL; ZIDOVUDINE; ZOMEPIRAC;

ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; GLUCURONIDATION; HUMAN; MOUSE; NONHUMAN; RABBIT; RAT; RISK ASSESSMENT; RISK FACTOR; SPECIES DIFFERENCE; TOXICITY; TOXICOKINETICS;

ANIMALS; GLUCURONIDES; HUMANS; MEDLINE; MODELS, BIOLOGICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHARMACOKINETICS; RISK ASSESSMENT; SPECIES SPECIFICITY;

ANIMALIA;

EID: 0034760101     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(01)00088-6     Document Type: Article

References (152)

1. Pharmacokinetics of antipyrine, paracetamol, and morphine in rat at 71 ATA
2. In vivo evaluation of zidovudine (AZT)-loaded ethylcellulose microspheres after oral administration in beagle dogs
3. Effect of cysteamine and cimetidine on acetaminophen (paracetamol) pharmacokinetics in rabbits
4. First pass conjugation and enterohepatic recycling of oxazepam in dogs; intravenous tolerance of oxazepam in propylene glycol
5. Pharmacokinetics of oxazepam in healthy volunteers
6. Disposition of clofibrate in the rat
7. Biliary excretion of conjugated hydroxyl benzodiazepines after administration of several benzodiazepines to rats, guinea pigs and mice
8. Analgesic and thermic responses to intravenously administered morphine in 8- and 24-week-old rats
9. Studies on the possible role of pharmacokinetics in the development of tolerance to morphine in the rat
10. Pharmacokinetics of valproic acid in volunteers after a single dose study
11. Pharmacokinetics and bioavailability of zidovudine in humans
12. Hepatic metabolism of diclofenac: Role of human CYP in the major oxidative pathways
13. Enantioselective disposition of salbutamol in man following oral and intravenous administration
14. Morphine metabolism in man
15. Does the animal-to-human uncertainty factor incorporate interspecies differences in surface area?
16. Species variation in the taurine conjugation of clofibric acid
17. Pharmacokinetics of morphine by radioimmunoassay: The influence of immunochemical factors
18. Clofibrate and clofibric acid: Comparison of the metabolic disposition in rats and dogs
19. Oxaprozin disposition in renal disease
20. Effects of food on oxaprozin bioavailability
21. Oxaprozin dose proportionality
22. Metabolism of 14-C-acetaminophen in humans and laboratory animals
23. Pharmacokinetic properties of carprofen in humans
24. Tissue distribution and metabolic disposition of zidovudine in rats
25. Lamotrigine: Chemistry and biotransformation
26. Dose dependent metabolism and enterohepatic recirculation of valproic acid in the rat
27. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats
28. Uncertainty factors for chemical risk assessment: Human variability in glucuronidation in relation to uncertainty factors for chemical risk assessment
29. Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZddU) in mice
30. Effect of mestranol on pharmacokinetics of paracetamol
31. Enterohepatic circulation of indomethacin and its role in intestinal irritation
32. Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats
33. Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits
34. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man
35. Paracetamol metabolism in two ethnically different Spanish populations
36. The metabolism of salbutamol in man
37. Dog liver N-methyltransferase (A drug-metabolizing enzyme)
38. Dose- and time-dependent elimination of acetaminophen in rats: Pharmacokinetic implications of cosubstrate depletion
39. Influence of advanced age on the formation and elimination of acetaminophen metabolites by male rats
40. Effect of aging on drug-metabolizing enzymes important in acetaminophen elimination
41. Pharmacokinetics of morphine and its surrogates III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose
42. Hepatic and extrahepatic glucuronidation of lorazepam in the dog
43. Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans
44. Species differences in the metabolism and disposition of antiviral nucleoside analogues: 2 Zidovudine
45. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans
46. Species variation in toxication and detoxication of acetaminophen in vivo: A comparative study of biliary and urinary excretion of acetaminophen metabolites
47. Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice
48. Metabolism and elimination of oxazepam in F344 rats
49. The metabolism of zomepirac sodium I (Disposition in laboratory animals and man)
50. Comparative bioavailability of two tablet formulations of diclofenac sodium in normal subjects
51. Intestinal absorption and first-pass elimination of 2′,3′-dideoxynucleosides following oral administration in rats
52. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations
53. Disposition of lorazepam in human beings: Enterohepatic recirculation and first-pass effect
54. Age-dependent changes in first-pass metabolism of acetaminophen in rats
55. Enterohepatic recirculation and renal metabolism of morphine in the rat
56. Effect of polycarbophil concentration on diclofenac sodium bioavailability from suppositories in beagle dogs
57. Effects of gender, pregnancy, and anesthesia on the pharmacokinetics of zidovudine in rats
58. Pharmacokinetics of morphine injected intravenously into the anaesthetized dog
59. Effect of infusion duration on valproate pharmacokinetics
60. Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats
61. First-pass effect of morphine in rats
62. Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats
63. Disposition of 4,5-diphenyl-2-oxazolepropionic acid (oxaprozin) in beagle dogs and rhesus monkeys
64. Metabolism and kinetics of oxaprozin in normal subjects
65. Disposition of oxaprozin in healthy subjects and certain disease states
66. Effects of diethyl ether anaesthesia on the pharmacokinetics of antipyrine and paracetamol in the rat
67. Metabolic rate of female rats as a function of age and body size
68. Effect of pregnancy on the disposition of valproate in rats
69. Pharmacokinetics and metabolism of azidothymidine in the dog
70. Species differences of site-selective glucuronidation of morphine
71. Comparison of bioavailability of salbutamol between oral and rectal administration in rabbits
72. Serum concentration and cardiovascular effects of salbutamol after oral and rectal administration in healthy volunteers
73. 100-Fold margin of safety
74. The pharmacological profile of oxaprozin, an antiinflammatory and analgesic agent with low gastrointestinal toxicity
75. Effect of experimental renal failure on sulfate retention and acetaminophen pharmacokinetics in rats
76. Effect of pregnancy on the pharmacokinetics of acetaminophen in rats
77. Pharmacokinetics and pharmacodynamics of valproate analogues in rats I. (Spiro[4,6]undecane-2-carboxylic acid)
78. Pharmacokinetics and pharmacodynamics of valproate analogs in rats III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat
79. Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose
80. The effect of malaria infection on paracetamol disposition in the rat
81. Metabolic studies of salbutamol-3H: A new bronchodilator, in rat, rabbit, dog and man
82. A rapid liquid chromatographic method for the determination of lamotrigine in plasma
83. The effect of different routes of administration on the metabolism of morphine: The disposition of morphine and its metabolites after topical application
84. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides in rabbits receiving single and repeated doses of morphine
85. A simple HPLC assay for urinary paracetamol metabolites and its use to characterize the C3H mouse as a model for paracetamol metabolism studies
86. Paracetamol metabolism in pregnancy
87. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate
88. Zomepirac kinetics in healthy males
89. Disposition pharmacokinetics of lorazepam in the rabbit
90. Disposition of zomepirac sodium in man
91. Cerebrospinal fluid uptake and peripheral distribution of centrally acting drugs: Relation to lipid solubility
92. Oxaprozin pharmacokinetics in patients with congestive heart failure
93. Metabolism of drugs. LXIX. Studied on the urinary metabolites of morphine in several mammalian species
94. Pharmacokinetics and tissue distribution of (+/-)-3′-azido-2′,3′-dideoxy-5′-O-(2-bromomyristoyl) thymidine, a prodrug of 3′-azido-2′,3′-dideoxythymidine (AZT) in mice
95. Lamotrigine: Absorption, distribution and excretion
96. Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats
97. Normal metabolism of morphine in cirrhosis
98. Salbutamol disposition and dynamics in conscious rabbits: Influence of the route of administration and of the dose
99. Comparative bioavailability of oral dosage forms of oxazepam. Correlation with in vitro dissolution rate
100. Effect of phenobarbital pretreatment on disposition of acetaminophen in mice
101. Physiologic and metabolic influences on enterohepatic recirculation: Simulations based upon the disposition of valproic acid in the rat
102. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure
103. Enantioselectivity of the enantioselective recycling of carprofen in the dog
104. The pharmacokinetics and metabolism of 14C-carprofen in man
105. Data-derived safety factors for the evaluation of food additives and environmental contaminants
106. Human variability and noncancer risk assessment-an analysis of the default uncertainty factor
107. The effect of HPMC - A cholesterol-lowering agent-on oral drug absorption in dogs
108. Effect of chloroquine and phenobarbital on morphine glucuronidation and biliary excretion in the rat
109. Diisopropylfluorophosphate increases clofibric acid clearance: Supporting evidence for a futile cycle
110. Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans
111. Comparative metabolism of lorazepam in man and four animal species
112. Relationship between the phasic period of interdigestive migrating contraction and the systemic bioavailability of acetaminophen in dogs
113. The toxicity and biotransformation of single doses of acetaminophen in dogs and cats
114. Biopharmaceutical studies on drug/conjugated-metabolite interactions II. Effect of acetaminophen sulfate on pharmacokinetics of acetaminophen in rats
115. Oral morphine in cancer patients: In vivo kinetics and in vitro hepatic glucuronidation
116. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen
117. Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs
118. Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (GAZT) in healthy subjects and HIV seropositive patients
119. Zidovudine disposition in patients with severe renal impairment: Influence of hemodialysis
120. The metabolic disposition of oxazepam in rats
121. Effects of diclofenac on irasdipine pharmacokinetics and platelet aggregation in volunteers
122. Bioavailability and pharmacokinetics of oxazepam
123. Single dose pharmacokinetics and pharmacodynamics of oxazepam in normal and renal dysfunction rats
124. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine
125. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. II. Quantitative determination of the unchanged drug and principal phenolic metabolites, in urine and bile
126. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites
127. Pharmacokinetics of zidovudine in patients with liver cirrhosis
128. UDP-glucuronyltransferases in the metabolic disposition of xenobiotics
129. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxyisobutyrate
130. Zidovudine bioavailability and linear pharmacokinetics in female B6C3F1 mice
131. Disposition and enterohepatic circulation of diclofenac in dogs
132. Dose-ranging pharmacokinetics of zidovudine (azidothymidine) in the rat
133. The bioavailability of diclofenac from enteric coated products in healthy volunteers with normal and artificially decreased gastric acidity
134. The influence of diflunisal on the pharmacokinetics of oxazepam
135. Extrapolation of animal toxicity to humans: Interspecies comparisons in drug development
136. The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs
137. Uncertainty factors for chemical risk assessment: Interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates
138. Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats
139. Effect of aspirin on a subtoxic dose of 14C-acetaminophen in mice
140. Principles for the safety assessment of food additives and contaminants in food
141. Assessing human health risks of chemicals: Derivation of Guidance values for health-based exposure limits
142. Principles for the assessment of risks to human health from exposure to chemicals
143. Lack of pharmacokinetic interaction between intravenous 2′,3′-dideoxyinosine and 3′-azido-3′-deoxythymidine in rats
144. The pharmacokinetics of diclofenac sodium following intravenous and oral administration
145. Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration
146. Distribution and fate of morphine in non-tolerant and tolerant dogs and rats
147. Evaluation of gastrointestinal transit controlled-beagle dog as a suitable animal model for bioavailability testing of sustained-release acetaminophen dosage form
148. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats
149. Metabolism of drugs. LXII. Isolation and identification of morphine glucuronides in urine and bile of rabbits
150. Toxicokinetics of oxazepam in rats and mice